Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 64

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 16
Chunk 64
---
ent consideration gains, restructuring charges and other3,602 — — Total$51,171 $47,895 $48,092 Stock-based compensation from:Stock options$21,730 $24,005 $26,800 RSUs28,656 22,974 20,310 ESPP share options785 916 982 Total$51,171 $47,895 $48,092 Related income tax benefit$10,506 $10,186 $10,219 

Pacira BioSciences, Inc.  |  2024 Annual Report on Form 10-K  |  Page F-34

Table of ContentsPACIRA BIOSCIENCES, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

The following table summarizes the Company’s stock option activity and related information for the year ended December 31, 2024:Number ofStock OptionsWeightedAverageExercise Price (Per Share)Weighted AverageRemainingContractualTerm (Years)AggregateIntrinsic Value(in Thousands)Outstanding at December 31, 20237,079,748 $49.40 6.03$863 Granted1,472,223 27.81 Forfeited(292,061)44.61 Expired(1,414,292)59.15 Outstanding at December 31, 20246,845,618 $42.95 5.72$804 Exercisable at December 31, 20244,420,578 $47.50 4.32$— Vested and expected to vest as of December 31, 20246,845,618 $42.95 5.72$804 As of December 31, 2024, $30.8 million of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a remaining weighted average period of 2.4 years. The Company’s stock options have a maximum expiration date of ten years from the date of grant. The weighted average fair value of stock options granted for the years ended December 31, 2024, 2023 and 2022 was $11.77, $15.92 and $25.60 per share, respectively. The fair values of stock options granted were estimated using the Black-Scholes model with the following weighted average assumptions: Year Ended December 31,